Celgene halts prostate cancer trial with Revlimid over lack of efficacy
This article was originally published in Scrip
Executive Summary
Celgene and its Swiss unit, Celgene International Sarl, halted a pivotal double-blinded Phase III trial evaluating the efficacy and safety of Revlimid (lenalidomide) as part of a treatment regimen with docetaxel and prednisone against castrate-resistant prostate cancer (CRPC) because it was no better than docetaxel and prednisone plus placebo in overall survival.